The PRECISION-T trial shows that ORCA-T, a precisely formulated graft with high regulatory T-cell and low conventional T-cell doses, dramatically improves chronic GVHD-free survival by 50 percentage points versus standard of care. This demonstrates that re-engineering the cell graft itself is a powerful prophylactic strategy beyond pharmacological intervention.

The VEHIT2 trial protocol, combining yanalumab and eltrombopag shortly after steroid failure, represents a paradigm shift. It moves beyond sequential single-agent therapy to explore if early, potent intervention can fundamentally reduce the long-term severity and chronic nature of ITP.

Pulsed dexamethasone provides no overall response rate benefit compared to a standard prednisone taper in first-line ITP treatment. It may offer a slightly faster response (by about one day) but carries a higher risk of acute steroid complications, particularly psychosis in older adults.

Contrary to common assumptions, standard initial steroid therapy is ineffective for the vast majority of adult ITP patients. Approximately 80% progress to chronic disease, highlighting the urgent need for more effective first- and second-line therapies to alter the disease course.

Despite being an FDA-approved option, ibrutinib is now rarely used for chronic GVHD. Real-world data reveals lower efficacy than in its pivotal trial (45% vs 60% ORR) and a high rate of discontinuation due to toxicity (42%). This demonstrates how newer agents with better risk-benefit profiles can quickly displace established therapies in clinical practice.

The treatment paradigm for ITP is shifting towards early combination therapy. Recent clinical trials are investigating augmented first- and second-line regimens, such as combining dexamethasone with rituximab or romiplostim, to achieve more durable, treatment-free responses than monotherapy.

A common theme across the four FDA-approved agents for steroid-refractory chronic GVHD (ibrutinib, belumosudil, ruxolitinib, axatilimab) is a high overall response rate driven primarily by partial remissions. The low rate of complete responses (CRs) highlights a significant unmet need and an opportunity for combination therapies or novel mechanisms.

Developers often test novel agents in late-line settings because the control arm is weaker, increasing the statistical chance of success. However, this strategy may doom effective immunotherapies by testing them in biologically hostile, resistant tumors, masking their true potential.

The approval of effective therapies like nirogacestat creates an ethical dilemma. For patients with progressing tumors, continuing to use a placebo arm in clinical trials may no longer be appropriate, challenging future research design for this rare disease.